PDGFRB and neoplasm: Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor (TKI), which can effectively inhibit VEGFR, PDGFR, FGFR, C-KIT and other kinases, and has anti-tumor angiogenesis and anti-tumor growth effects [5–8].